Senores Pharma has niche positives, can be a long-term bet

Incorporated in 2017, the company identifies, develops and commercialises speciality and complex niche products in mid-market range. It also undertakes contract manufacturing for its customers. It earns through in-licensing fee, transfer pricing and profit sharing. Over 60% of its revenues come from supplying to regulated markets of the US, Canada and the UK and 32% from emerging markets. Incorporated in 2017, the company identifies, develops and commercialises speciality and complex niche products in mid-market range. It also undertakes contract manufacturing for its customers. It earns through in-licensing fee, transfer pricing and profit sharing. Over 60% of its revenues come from supplying to regulated markets of the US, Canada and the UK and 32% from emerging markets.  Economic Times

Leave a Reply

Your email address will not be published. Required fields are marked *